Stereotaxis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stereotaxis, Inc. on January 5, 2011, regarding events occurring on January 3, 2011. The filing details a material definitive agreement entered into with Biosense Webster, Inc., a long-standing strategic partner since 2002. The companies collaborate to integrate Biosense Webster's catheter location sensing technology with Stereotaxis's Niobe Magnetic Navigation System.
Key Financial Metrics and Obligations
The filing does not provide current period revenue, profit, or cash flow statements. However, it discloses specific financial obligations related to the partnership:
- Outstanding Obligations: As of September 30, 2010, the remaining balance of advances and deferred payments owed to Biosense Webster was $9.6 million.
- Repayment Terms: These obligations are recouped via revenue share payments or periodic minimum payments. Any remaining balance is due by December 31, 2011.
- Termination Fees: In the event of a "change of control," Stereotaxis may be required to pay a termination fee equal to 5% of its total equity valuation, capped at $10 million.
- Additional Contingent Fee: If a change of control occurs after FDA approval for the Navistar RMT Thermocool catheter for atrial fibrillation, an additional $10 million fee is payable to Biosense Webster.
Material Changes and Agreement Terms
The Sixth Amendment and Catheter and Mapping System Extension modifies the existing Development Alliance and Supply Agreement with the following key changes:
- Extended Distribution Rights: Biosense Webster's exclusive distribution rights for existing co-developed products are extended until December 15, 2015, followed by non-exclusive rights through December 31, 2018. Rights in Japan are extended to the later of December 31, 2017 (exclusive) or December 31, 2020 (non-exclusive).
- New Product Development: The parties agreed to collaborate on a new product based on Biosense Webster's next-generation irrigated catheter. Biosense Webster will receive revenue shares and exclusive worldwide distribution rights for five years post-FDA approval.
- Regulatory Pursuits: Biosense Webster agreed to pursue an expanded U.S. indication for the Navistar RMT Thermocool catheter for the treatment of atrial fibrillation.
- Revenue Sharing: The revenue sharing arrangement has been updated to reflect the extended terms.
Outlook, Risks, and Contingencies
Management commentary is limited to the terms of the agreement and a standard forward-looking statements disclaimer. Key risks and contingencies include:
- Change of Control Penalties: The agreement imposes significant financial liabilities ($10 million cap plus potential additional $10 million) if the company is acquired or undergoes a change of control, potentially complicating M&A transactions.
- Regulatory Approval: Future revenue and fee obligations are contingent upon obtaining FDA approvals for the new product and the expanded indication for the Navistar catheter.
- Liquidity Pressure: The $9.6 million obligation due by December 31, 2011, if not recouped through revenue shares, represents a near-term liquidity requirement.
Investor Verification Checklist
- Verify the current status of the $9.6 million obligation and whether revenue shares are sufficient to cover the December 31, 2011, maturity date.
- Confirm the progress of the FDA application for the expanded atrial fibrillation indication for the Navistar RMT Thermocool catheter.
- Assess the impact of the $10 million termination fee cap on potential future acquisition valuations.
- Review the specific revenue sharing percentages updated in the Sixth Amendment to estimate future royalty income.